Researchers in Iran reported the first case of myasthenia gravis (MG) following a Sinopharm vaccination against SARS-CoV-2, the virus that causes COVID-19. The report follows evidence of a possible link between COVID-19 vaccination and MG. While the mechanisms remain unclear, “if muscle weakness, ocular and bulbar [neck and facial]…
News
Subcutaneous immunoglobulin therapy (SCIg) — given by under-the-skin injection — was well-tolerated and effective in the management of adults with myasthenia gravis (MG), a small study has found. Although the therapy is approved for other diseases related to immune system deficiency, and is currently under investigation as an…
Neurologists find both Vyvgart (efgartigimod) and Ultomiris (ravulizumab-cwvz) effective for treating generalized myasthenia gravis (gMG), but believe Ultomiris has a more convenient dosing schedule while Vyvgart may have a better safety profile. That’s according to a recent analysis by the market intelligence firm Spherix Global Insights.
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Ultomiris (ravulizumab) for treating generalized myasthenia gravis (gMG). The approval covers adults positive for antibodies against the acetylcholine receptor (AChR) — the most common type of MG-driving autoantibody — and who either don’t respond adequately to…
Risk factors for converting ocular myasthenia gravis (MG) to generalized myasthenia gravis (gMG) after a thymectomy, or thymus removal surgery, were identified in a recent study. Specifically, abnormalities in a repetitive nerve stimulation (RNS) test and having a specific thymus tumor subtype called B2/B3 were predictive of gMG…
Levels of the tumor necrosis factor receptor-associated factor 6 (TRAF6) protein in immune B-cells are higher than normal in people with myasthenia gravis (MG), and may be a useful biomarker of inflammation in MG, a study suggested. The observed elevations were more pronounced among patients with generalized MG…
About one in 10 patients with thymic carcinoma — a rare type of malignant tumor in the thymus gland — also has myasthenia gravis (MG), but this does not appear to reduce their lifespan, according to a study of data from an international registry. The study, “Does myasthenia…
Researchers in Italy have reported three cases of myasthenia gravis (MG) they say may possibly have been caused by a vaccine against SARS-CoV-2, the virus that causes COVID-19. “Clinicians should be aware of possible new-onset MG after SARS-CoV-2 vaccination, especially with the current recommendation of booster doses,” the team…
The European Commission has approved Vyvgart (efgartigimod) as an add-on to standard treatment for adults with generalized myasthenia gravis (gMG) who are positive for antibodies against acetylcholine receptor (AChR), the most common type of MG-driving antibody. “We share the excitement with the European gMG community in bringing a…
Sanofi has decided to pause recruitment globally in its Phase 3 clinical trials of tolebrutinib, an experimental BTK inhibitor, based on recommendations from the independent data monitoring committee (iDMC) overseeing the trials. The company has several ongoing studies investigating tolebrutinib’s effectiveness and safety, including one testing the investigational therapy…
Recent Posts
- The 3 to 5 minutes that act as music therapy for my brother with MG
- Doctors say MG doesn’t cause pain, but my body suggests otherwise
- Taking Vyvgart before thymectomy may help improve surgery outcomes
- Finding ways to reduce suffering, even while living with chronic pain
- Guest Voice: What living between labels taught me about MG